

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/028270-2022>

Tender

Electronic Quality Management System (eQMS) for Medicines Discovery Catapult

Medicines Discovery Catapult

F02: Contract notice

Notice identifier: 2022/S 000-028270

Procurement identifier (OCID): ocds-h6vhtk-0373f4

Published 7 October 2022, 2:30pm

Section I: Contracting authority

I.1) Name and addresses

Medicines Discovery Catapult

Block 35, Mereside, Alderley Park

Cheshire

SK10 4ZF

Contact

James Tomlinson

Email

james.tomlinson@md.catapult.org.uk

Telephone

+44 1625708394

Country

United Kingdom

Region code

UK - United Kingdom

Internet address(es)

Main address

<https://md.catapult.org.uk/>

Buyer's address

<https://md.catapult.org.uk/>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://procontract.due-north.com/RFx/RFxSummary?rfxId=532e9bbc-1846-ed11-811a-005056b64545&projectId=482d48e6-1046-ed11-811a-005056b64545>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://procontract.due-north.com/RFx/RFxSummary?rfxId=532e9bbc-1846-ed11-811a-005056b64545&projectId=482d48e6-1046-ed11-811a-005056b64545>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Other activity

Drug Discovery / Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Electronic Quality Management System (eQMS) for Medicines Discovery Catapult

Reference number

DN636698

II.1.2) Main CPV code

- 72000000 - IT services: consulting, software development, Internet and support

II.1.3) Type of contract

Services

II.1.4) Short description

Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.

MDC requires a robust Electronic Quality Management System (eQMS) to support business growth and new projects involving clinical samples. The new eQMS is required to provide full traceability for all activities pertaining to clinical samples, whilst also supporting MDC's operations at large.

Further information can be found at <https://procontract.due-north.com/RFx/RFxSummary?rfxId=532e9bbc-1846-ed11-811a-005056b64545&projectId=482d48e6-1046-ed11-811a-005056b64545>

II.1.5) Estimated total value

Value excluding VAT: £455,000

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

Medicines Discovery Catapult (MDC) is a national facility for collaborative R&D exploring and developing new approaches to the discovery and proof of well targeted medicines, diagnostics and biomarkers. Funded by Innovate UK, an agency of the UK government, MDC are an independent not-for-profit company bringing together a fragmented UK sector of industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high value products. By sharing problems, rare expertise and assets we support the growth of this new community through a time of radical business and national change.

MDC requires a robust eQMS to support business growth and new projects involving clinical samples. The new eQMS is required to provide full traceability for all activities pertaining to clinical samples, whilst also supporting MDC's operations at large.

An open procurement procedure is being used.

Further information can be found at <https://procontract.due-north.com/RFx/RFxSummary?rfxId=532e9bbc-1846-ed11-811a-005056b64545&projectId=482d48e6-1046-ed11-811a-005056b64545>

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 January 2023

End date

31 December 2030

This contract is subject to renewal

Yes

Description of renewals

This is an initial 3-year contract, with the option to extend for a further four separate 1-year periods subject to the awarded suppliers satisfactory performance.

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

7 November 2022

Local time

3:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.7) Conditions for opening of tenders

Date

7 November 2022

Local time

3:00pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

Medicines Discovery Catapult

Block 35, Mereside, Alderley Park,

Cheshire

Country

United Kingdom